Sentences with phrase «functional cure for type»

As the first company to advance a cell replacement therapy for type 1 diabetes into the clinic, ViaCyte is committed to developing a functional cure for all type 1 diabetes patients.

«ViaCyte's mission to create a functional cure for type 1 diabetes is well - aligned with Beyond Type 1's goals, and we are delighted to have the opportunity to support them and facilitate the rapid development of their promising product candidates for type 1 diabetes.»

SAN DIEGO and SAN FRANCISCO, February 23, 2017 — ViaCyte, Inc., a privately - held regenerative medicine company, and Beyond Type 1, a not - for - profit advocacy and education group for those living with type 1 diabetes, today announced a grant from Beyond Type 1 to support ViaCyte's efforts to develop a functional cure for type 1 and other insulin - requiring diabetes.

Not exact matches

Regenerative medicine application for adrenal disorders have been neglected compared to other endocrine fields, such as the word - wide effort to generate functional endocrine pancreas to cure type - I diabetes.

The company's lead PEC - DirectTM product candidate is entering clinical development as a potential functional cure for patients with type 1 diabetes with the highest risk of life threatening acute complications.

After implantation, the cells are expected to mature into the full complement of islet cells, including insulin - producing beta cells, offering a potential functional cure for patients with high - risk type 1 diabetes.

In addition, we believe that success with PEC - Direct is an important step on the path to a functional cure for all patients with type 1 diabetes, helping to fulfill our commitment of turning Type One into Type None.&ratype 1 diabetes, helping to fulfill our commitment of turning Type One into Type None.&raType One into Type None.&raType None.»

To deliver a functional cure for all patients with type 1 diabetes and an important new therapy for patients with type 2 disease that require insulin to maintain control, ViaCyte is developing products with numerous advantages including a virtually unlimited supply of cells manufactured under quality - controlled conditions, and a potentially safer and more optimal route of administration.

Used with concomitant maintenance immune suppression therapy, the PEC - Direct product has the potential of delivering a sustained, functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.

While PEC - Direct development could advance more rapidly and make a major impact for the subset of type 1 diabetes patients at highest risk, we view PEC - EnCap as holding the promise of a functional cure for all patients with type 1 diabetes as well as an important therapy for many patients with type 2 diabetes.»

«We are tremendously grateful for the financial and social support that Beyond Type 1 is providing to ViaCyte as we work to create a functional cure for people with type 1 diabetes.&raType 1 is providing to ViaCyte as we work to create a functional cure for people with type 1 diabetes.&ratype 1 diabetes.»

San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.

Chris Kresser, M.S., L.Ac., is the founder of Kresser Institute, the co-director of the California Center for Functional Medicine, the creator of ChrisKresser.com, and The New York Times bestselling author of The Paleo Cure: Eat Right for Your Genes, Body Type, and Personal Health Needs.